Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Regenovo, formally known as Hangzhou Jienuofei Biotechnology, is a China-based biomedical 3D printing company focused on integrated solutions spanning bioprinters, biomaterials, software, imaging, and automated bio-manufacturing systems. The company serves research and translational medicine use cases in regenerative medicine, tissue engineering, drug discovery, and personalized healthcare rather than operating like a traditional therapeutics developer. Its offerings include bioprinting hardware, bio-inks and related materials, imaging and analysis systems, and manufacturing solutions for cells and tissue constructs. Regenovo appears to be an active private company headquartered in Hangzhou, Zhejiang, with commercialized products and services for laboratories, hospitals, and research institutions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Regenovo.